EMA
withdrawal
· 2008-03-20
EMA Refused: Cimzia (certolizumab pegol) — UCB Pharma SA
Summary
EMA decision refused approval for Cimzia (certolizumab pegol) for Crohn's disease. The marketing authorization application was not granted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Refused. Therapeutic area: Crohn Disease. MAH: UCB Pharma SA. Decision date: 20/03/2008